Ostarine MK-2866 For Sale — The Most Studied SARM
Ostarine MK-2866 (Enobosarm, GTx-024) — the only SARM to reach Phase III clinical trials. The most selective and most studied SARM in the published literature. Independently verified to ≥99% purity. Triple-tested every batch. 50ml — 1,250mg total. Free US shipping over $100.
Third-Party COA
Phase III Clinical Data
USA Manufactured
50ml · 1,250mg Total
Free Shipping $100+
4.90 / 5 — 161 verified research reviews
Research Compound Overview
Ostarine MK-2866 For Sale — What Makes It the Gold Standard SARM
Ostarine MK-2866 (Enobosarm, GTx-024) is a nonsteroidal selective androgen receptor modulator (SARM) originally developed by GTx, Inc. It holds a unique position in SARM research: it is the only SARM to advance through Phase II and Phase III clinical trials, making it the most clinically validated and most extensively studied SARM in the published literature.
When you find Ostarine MK-2866 for sale from Chemyo, every batch is independently verified to ≥99% purity via HPLC and Mass Spectrometry, with independent concentration testing — not just purity. Every Certificate of Analysis is published publicly and searchable by lot number.
AMSBIO sells Ostarine (catalog AMS-T2408) as a life science reagent in 25mg–50mg vials — sourced from TargetMol, priced at institutional reagent rates for in vitro cell-based assay work. Chemyo sells Ostarine MK-2866 as a practical research SARM in 50ml bottles at 25mg/ml — 1,250mg total — with independent concentration verification, publicly searchable COA by lot number, and same-day USA dispatch. If you need Ostarine for practical protocol-scale SARM research, Chemyo is the correct source.
Ostarine is the most widely used name. Enobosarm is the INN (official generic name). MK-2866 is Merck’s developmental code. GTx-024 is GTx, Inc.’s code. S-22 is the synthesis paper code. VERU-024 is Veru Inc.’s current development code. All refer to the same molecule — CAS 841205-47-8. Chemyo sells MK-2866 free base, the standard form for all published clinical research.
Ostarine MK-2866 Specifications at Chemyo
| Compound Name | Ostarine (MK-2866, Enobosarm, GTx-024, S-22) |
| CAS Number | 841205-47-8 |
| Class | Nonsteroidal SARM (Selective Androgen Receptor Modulator) |
| Molecular Formula | C₁₉H₁₄F₃N₃O₃ |
| Molecular Weight | 389.33 g/mol |
| Clinical Stage | Phase II & Phase III (most advanced SARM) |
| Purity (Chemyo) | ≥99% HPLC verified |
| Identity Testing | Mass Spectrometry — every batch |
| Concentration Testing | Independent lab — every batch |
| Bottle Volume | 50ml (vs 30ml industry standard) |
| Concentration (liquid) | 25mg/ml |
| Total per bottle | 1,250mg total |
| Half-Life | ~24 hours (oral, animal models) |
| Available Forms | Liquid 25mg/ml · Powder 1g |
| Intended Use | Research purposes only — not for human use |
Buyer’s Guide
3 Places to Find Ostarine MK-2866 For Sale — Compared
Not all Ostarine MK-2866 for sale is the same product for the same purpose. Here’s how the three main source types compare for practical research use.
Purpose-built for protocol-scale SARM research. 50ml · 25mg/ml · 1,250mg total.
- ✓HPLC + Mass Spec + concentration tested
- ✓Public COA by lot number
- ✓1,250mg total at $0.056/mg
- ✓Same-day USA dispatch
- ✓Induction sealed · Free ship $100+
Institutional reagent supplier. 25mg–50mg vials for in vitro assay work.
- ✓High purity reagent grade
- ✓ISO9000 certified supplier
- ✗No concentration testing published
- ✗50mg only — not for protocol scale
- ✗Ships internationally — longer delivery
Variable quality, limited testing documentation, long international shipping.
- ✓Sometimes lower upfront price
- ✗No independent COA
- ✗No concentration verification
- ✗2–6 week international delivery
- ✗Unknown manufacturing standards
Vendor Comparison
Chemyo vs AMSBIO — Ostarine MK-2866 For Sale Full Comparison
| Standard | Chemyo | AMSBIO (AMS-T2408) |
|---|---|---|
| Product type | Research SARM — protocol scale | Life science reagent — assay scale |
| Purity testing (HPLC) | ✓ ≥99% every batch | ✓ High purity |
| Identity testing (Mass Spec) | ✓ Every batch | Not publicly confirmed |
| Concentration testing | ✓ Independent lab | ✗ Not published |
| Public COA by lot number | ✓ Searchable online | ✗ Not available |
| Quantity per unit | 1,250mg (50ml / 25mg/ml) | 25mg or 50mg vials |
| Price per mg | ~$0.056/mg | ~$5–10/mg (assay pricing) |
| Ships from | USA — same-day dispatch | UK / Europe — international |
| Delivery to USA | 3–7 business days | 7–21 days (international) |
| Free US shipping | ✓ Orders $100+ | ✗ No |
| Induction sealed | ✓ Tamper-proof | Standard reagent vial |
AMSBIO is an ISO9000-certified life science supplier — excellent for institutional reagent procurement. For protocol-scale Ostarine MK-2866 research, Chemyo provides superior value, verification, and delivery speed.
Why Chemyo
Why Researchers Buy Ostarine MK-2866 For Sale From Chemyo
Identity (Mass Spec) + Purity (HPLC ≥99%) + Concentration — independently tested every batch by a third-party lab. AMSBIO does not publish independent concentration testing. Without it, you cannot confirm the label matches what’s in the vial.
AMSBIO’s 50mg vials at institutional reagent pricing are designed for assay work — not multi-week research protocols. Chemyo’s 50ml bottle delivers 1,250mg at $0.056/mg. Scale, value, and form all optimized for practical SARM research.
All Chemyo orders ship from the USA — same-day before 2PM EST, arriving in 3–7 business days. AMSBIO ships internationally from the UK/Europe. For time-sensitive research, domestic USA fulfilment is critical.
Preclinical & Clinical Research Overview
Ostarine MK-2866 Research: The Most Advanced SARM in Clinical Data
Ostarine MK-2866 has the most extensive clinical research profile of any SARM — the only compound in this class to advance through Phase III trials. All data reflects animal model and early clinical findings. Ostarine is not FDA-approved for human use.
Primary Research Areas
- ✓
Muscle Wasting & Cachexia (Phase III): Ostarine reached Phase III clinical trials for cancer-related muscle wasting — the most advanced clinical application of any SARM. Published Phase III data evaluated lean mass preservation in oncology patients, establishing the most robust clinical dataset in the SARM category.
- ✓
Lean Body Mass (Phase II): Phase II trials in healthy elderly adults show statistically significant lean mass increases — with the selectivity profile limiting androgenic side effects in non-target tissues. This tissue selectivity is Ostarine’s defining research advantage over more potent but less selective SARMs.
- ✓
Bone Density (Phase II): Phase II data shows Ostarine increases bone mineral density — studied in osteoporosis and postmenopausal models with established efficacy signals and a favorable side effect profile compared to testosterone-based interventions.
- ✓
Insulin Sensitivity (Phase II): A unique finding in Phase II data — Ostarine improved insulin sensitivity and fasting blood glucose in elderly subjects. This metabolic effect, absent from most other SARMs, opens a distinct research direction linking AR activation and glucose metabolism.
- ✓
Breast Cancer Research (AR+/ER+): Currently under development as VERU-024 by Veru Inc. for androgen receptor-positive breast cancer — one of the most clinically significant oncology research applications of any SARM, with active IND status as of 2026.
- ✓
GLP-1 Combination Research: Ostarine is being evaluated in combination with GLP-1 receptor agonists (like semaglutide) for body composition improvement — specifically to preserve lean mass during GLP-1-induced weight loss. An emerging 2025–2026 research direction with strong clinical rationale.
Legal Status in 2026
Ostarine MK-2866 is legal to purchase in the USA as a research compound. Not a controlled substance, not DEA-scheduled. No prescription required for research. Chemyo sells Ostarine in full US regulatory compliance — research use only.
Research Reference
Ostarine MK-2866 Dosage Reference — Preclinical & Clinical Data Only
Summarized from published research. For reference only. Not a recommendation for human use.
| Research Protocol | Reported Dose | Route | Duration |
|---|---|---|---|
| Muscle Tissue (rodent) | 0.04–4 mg/kg/day | Oral gavage | 7–28 days |
| Lean Body Mass (Phase II) | 1–3 mg/day | Oral | 12 weeks |
| Bone Density (Phase II) | 0.1–3 mg/day | Oral | 12–24 weeks |
| Cachexia — Phase III | 1–3 mg/day | Oral | 4–6 months |
| Insulin Sensitivity (Phase II) | 3 mg/day | Oral | 12 weeks |
| Breast Cancer (VERU-024) | 9–18 mg/day (Phase II) | Oral | 24 weeks |
Data from peer-reviewed preclinical and Phase I/II/III clinical literature. Ostarine is not FDA-approved. Human use not endorsed.
Frequently Asked Questions
Ostarine MK-2866 For Sale — Buyer FAQs
Related SARM Research Compounds
Researchers studying MK-2866 (Ostarine) Powder – 1g often also explore
LGD-4033,
RAD140, and
YK-11 for broader anabolic and androgen receptor research models.
For lean mass and metabolic efficiency studies, MK-2866 is frequently evaluated alongside
Cardarine (GW501516) and
MK-677 in performance research protocols.
Powder-based research workflows often require precise measuring tools such as
1ml Dropper Bottles for consistent dosing and reproducible laboratory results.
Reviews
There are no reviews yet.